Cyclooxygenase-2 expression during carcinogenesis in the human stomach

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• Prolonged non-steroidal anti-inflammatory drug (NSAID) use correlates with reduced gastric cancer risk.
• Cyclooxygenase-2 (COX-2) is a key target of NSAIDs and is often upregulated in gastric adenocarcinomas.

Purpose of the Study:

• To investigate the expression patterns of COX-2 mRNA and protein during gastric tumor progression in post-gastrectomy human stomach samples.
• To determine if COX-2 expression is an early event in gastric carcinogenesis.

Main Methods:

• Utilized reverse transcriptase polymerase chain reaction (RT-PCR) to quantify COX-2 mRNA levels.
• Employed immunohistochemistry to assess COX-2 protein expression and its co-localization with various cellular markers (CD68, alpha-SMA, vimentin, HLA-DR).
• Examined tissue samples from different stages of gastric lesion progression, including intestinal metaplasia and high-grade dysplasia.

Main Results:

• COX-2 mRNA levels were elevated in intestinal metaplasia.
• COX-2 protein expression increased progressively from reactive epithelium to high-grade dysplasia, in both epithelial and stromal cells.
• COX-2 was localized in the cytoplasm of neoplastic cells and showed co-localization with several stromal markers, though a distinct stromal cell subpopulation remained unidentified.

Conclusions:

• COX-2 expression is an early event in gastric carcinogenesis.
• Increased COX-2 expression correlates with tumor progression in the stomach.
• These findings suggest a significant role for COX-2 in the development and progression of gastric cancer.